Smits Anke, Ten Eikelder Mieke, Dhanis Joelle, Moore William, Blake Dominic, Zusterzeel Petra, Kucukmetin Ali, Ratnavelu Nithya, Rundle Stuart
Dept. of Obstetrics and Gynaecology, Radboud University Medical Center, 6525, GA, Nijmegen, the Netherlands; Dept. of Gynecological Oncology, Queen Elizabeth Hospital, NE9 6SX, Gateshead, United Kingdom.
Dept. of Obstetrics and Gynaecology, Radboud University Medical Center, 6525, GA, Nijmegen, the Netherlands.
Gynecol Oncol. 2023 Mar;170:84-92. doi: 10.1016/j.ygyno.2022.12.013. Epub 2023 Jan 17.
To report our institutional experience with sentinel lymph node (SLN) detection using indocyanine green for cervical cancer, in terms of detection rates, detection of SLN at unusual locations, and factors associated with unusual SLN locations. In addition, we performed a systematic review of the literature to identify factors associated with unusual SLN localizations.
This is a retrospective cohort study of women with early-stage cervical cancer undergoing sentinel lymph node mapping between 2015 and 2019. Outcome measures were SLN detection rates, detection rates of unusual locations for SLN and risk factors for aberrant lymphatic drainage pathways. In addition, studies evaluating factors associated with unusual SLN locations in cervical cancer were assessed in a systematic review.
A total of 100 patients were included. The unilateral SLN detection rate was 88%, whereas the bilateral detection rate was 75%. In 37% of all patients, SLN were found in unusual locations, and in 10% of patients SLN were solely found in unusual locations. Body mass index (BMI) was associated with finding SLN in unusual locations, with unusual nodes detected in 52% of patients with BMI <25 kg/m and in 28% of patients with BMI ≥25 kg/m. The systematic review identified three studies, identifying lower BMI, nulliparity and tumor size of >20 mm as factors associated with finding SLN at unusual locations.
Aberrant drainage sites represent a significant proportion of SLN detected in cervical cancer. Factors associated with increased rates of unusual nodal locations are a lower BMI, with a possible association with nulliparity and tumor size of >20 mm.
报告我们机构使用吲哚菁绿检测宫颈癌前哨淋巴结(SLN)的经验,包括检测率、在不寻常位置检测到SLN的情况以及与不寻常SLN位置相关的因素。此外,我们对文献进行了系统回顾,以确定与不寻常SLN定位相关的因素。
这是一项对2015年至2019年间接受前哨淋巴结定位的早期宫颈癌女性进行的回顾性队列研究。观察指标为SLN检测率、SLN在不寻常位置的检测率以及异常淋巴引流途径的危险因素。此外,在一项系统回顾中评估了评估宫颈癌中与不寻常SLN位置相关因素的研究。
共纳入100例患者。单侧SLN检测率为88%,双侧检测率为75%。在所有患者中,37%的患者SLN位于不寻常位置,10%的患者SLN仅位于不寻常位置。体重指数(BMI)与在不寻常位置发现SLN相关,BMI<25kg/m²的患者中有52%检测到异常淋巴结,BMI≥25kg/m²的患者中有28%检测到异常淋巴结。系统回顾确定了三项研究,确定较低的BMI、未生育和肿瘤大小>20mm是与在不寻常位置发现SLN相关的因素。
异常引流部位占宫颈癌中检测到的SLN的很大比例。与异常淋巴结位置增加率相关的因素是较低的BMI,可能与未生育和肿瘤大小>20mm有关。